Hayden is an assistant editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2021, where she produces written and video content covering multiple disease states.
She has a BA in journalism & media studies from Rutgers University. You can connect with Hayden on LinkedIn.
Dr Steven Pipe: What to Watch for in the Hemophilia Therapy Pipeline
December 10th 2022The field of hemophilia therapy is advancing, with hemostatic rebalancing agents and gene therapy expected over the next year, said Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory.
Read More
Dr Emma Searle Previews MajesTEC-2 Data to Be Presented at ASH 2022
December 7th 2022Emma Searle, PhD, consultant hematologist, The Christie Hospital NHS Foundation Trust, touches on key points learnt from MajesTEC-2 data and other data to look forward to at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
Read More
Dr Neil Iyengar Previews SABCS Presentation on Metabolic Dysregulation in Breast Cancer
December 5th 2022Neil Iyengar, MD, from Memorial Sloan Kettering Cancer Center, is expecting updates on therapies to fight human epidermal growth factor 2 (HER2)–positive breast cancer and novel antibody drug conjugates at the upcoming San Antonio Breast Cancer Symposium (SABCS).
Read More
Dr Steven Pipe on Current Trends in Hemophilia Incidence
December 2nd 2022About 1 in 5000 males are born with hemophilia, according to Steven W. Pipe, MD, a professor of pediatrics and pathology at the University of Michigan, Ann Arbor and medical director of the Pediatric Hemophilia and Coagulation Disorders Program.
Read More
Dr Kevin Astle: Long-Acting Injectables Are a Game Changer for Adherence
November 26th 2022Now that long-acting injectables are approved, the next big concern is patient access, said Kevin N. Astle, PharmD, BCPS, BCACP, AAHIVP, CDES, assistant professor at the University of South Florida Taneja College of Pharmacy.
Read More
T1D Index Will Be Updated Annually, JDRF’s Tom Robinson Explains
November 24th 2022Updating the Type 1 Diabetes (T1D) Index each year with the latest data and literature and implementing feedback is important for at least the first few years, said Tom Robinson, vice president of global access at JDRF.
Read More
Long-Acting Injectables Promote PrEP Access, Adherence, Says Dr Tam Phan
November 22nd 2022Tam C. Phan, PharmD, AAHIVP, assistant professor of clinical pharmacy, USC School of Pharmacy, talks about how HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline address disparities in patient access and adherence.
Read More
MA Beneficiaries May Be at Disadvantage for Complex Cancer Surgeries
November 21st 2022Patients with Medicare Advantage (MA) were 1.5 times more likely to die within a month of surgical removal of their stomach or liver, and twice as likely to die within a month of oncologic surgery of the pancreas, compared with patients with traditional Medicare.
Read More
Dr Nancy Reau Covers Alcohol Use Disorder Interventions to Prevent Alcoholic Hepatitis
November 19th 2022As patients come into clinic and receive appropriate follow-up, we can hopefully find ways to mitigate the increase in alcoholic hepatitis, said Nancy Reau, MD, section chief of hepatology at Rush University Medical Center.
Read More
JDRF's Tom Robinson Expands on Policies to Ensure Implementation, Access to Key T1D Interventions
November 19th 2022Get type 1 diabetes (T1D) communities involved in solving the problem and implementing T1D interventions in your country, said Tom Robinson, vice president of global access at JDRF.
Read More
JDRF's Tom Robinson Highlights Key T1D Interventions
November 16th 2022While each country has a different priority when it comes to type 1 diabetes (T1D) diagnosis and treatment, there is a fairly consistent outcomes checklist across nations, said Tom Robinson, vice president of global access at JDRF.
Read More
Stem Cell Transplant May Be Viable Treatment for Patients With HIV, Leukemia, Says Dr Jana Dickter
November 16th 2022Jana K. Dickter, MD, associate clinical professor, Division of Infectious Diseases, City of Hope, discusses a patient's experience being the oldest person to successfully undergo a stem cell transplant while living with HIV and leukemia.
Read More
OneOncology’s Clinical Pathways Covers Best Practices for 90% of Patients, Says Dr Ted Arrowsmith
November 13th 2022The disease groups that make up the OneOncology clinical pathways program cover 90% of patients with cancer and develop best practices for treating cancer in the majority of patients, said Edward “Ted” Arrowsmith, MD, MPH, managing partner and director of research, East Tennessee Division, Tennessee Oncology.
Read More
Dr Davey Daniel Hits the High Points of the OneOncology Annual Conference
November 12th 2022The OneOncology Annual Conference is being held November 11-13 in Nashville, Tennessee, and brings together practice leaders, physicians, and advanced practice providers to discuss the business of oncology and scientific advancements, explained Davey Daniel, MD, chief medical officer of OneOncology.
Read More
Dr Joseph Alvarnas Explains Barriers to Clinical Trial Diversity and Payer Participation
November 11th 2022For the US health care system to be appropriately patient-centered, clinical trials need to be reflective of the country's diversity, said Joseph Alvarnas, MD, vice president of government affairs and senior medical director for employer strategy at City of Hope.
Read More
Dr Debra Patt: DESTINY-Breast04 Realizes a Promise of Modern Cancer Therapy
November 11th 2022Debra Patt, MD, PhD, MBA, executive vice president of public policy and strategic initiatives at Texas Oncology, expands on her keynote address at the 2022 meeting of Patient-Centered Oncology Care®, which focused on DESTINY-Breast04 study findings and their applicability to managed care.
Read More
Dr Jeffrey Patton on Setting Standards of Care Through OneOncology’s Clinical Pathways Program
November 11th 2022Representatives across 12 disease groups make up a council that sets clinical recommendations for oncology care and those decisions are being pushed out in the electronic medical record for decision support at the point of care, said Jeffrey Patton, MD, CEO, OneOncology, and executive chairman of the board, Tennessee Oncology. Patton will lead off OneOncology's Physician Leadership Conference, which runs November 11-13 in Nashville.
Read More